HLB Life Science (067630) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, HLB Life Science (067630) reported revenue of 45.8 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
202545.8 billion KRW-22.0 billion KRW-99.9 billion KRW[source]
2024102.2 billion KRW-24.8 billion KRW6.2 billion KRW[source]
202398.0 billion KRW-24.5 billion KRW-5.9 billion KRW[source]
202299.6 billion KRW-20.2 billion KRW-54.4 billion KRW[source]
202153.5 billion KRW-18.5 billion KRW-49.3 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025441.8 billion KRW125.7 billion KRW316.0 billion KRW[source]
2024496.1 billion KRW104.0 billion KRW392.0 billion KRW[source]
2023415.0 billion KRW181.6 billion KRW233.4 billion KRW[source]
2022405.2 billion KRW165.0 billion KRW240.2 billion KRW[source]
2021271.2 billion KRW13.6 billion KRW257.7 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice